The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).
KPC Pharmaceuticals, a subsidiary of China Resources Pharmaceutical Group Ltd., reported a decline in revenue and net profit for the first quarter of 2025 compared to the same period in 2024. The unaudited financial results indicate a decrease in cash and cash equivalents, with total assets slightly increasing while liabilities decreased marginally. Stakeholders are advised to exercise caution as the financials are unaudited and may require adjustments.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company holds a significant equity interest in KPC Pharmaceuticals, which is listed on the Shanghai Stock Exchange.
YTD Price Performance: -19.26%
Average Trading Volume: 1,550
Technical Sentiment Signal: Buy
Current Market Cap: €3.51B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.